{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:06:47Z","timestamp":1759482407097},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"27","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1097\/md.0000000000004113","type":"journal-article","created":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T16:35:39Z","timestamp":1467995739000},"page":"e4113","source":"Crossref","is-referenced-by-count":12,"title":["A case report"],"prefix":"10.1097","volume":"95","author":[{"given":"Hui","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui E.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya Lan","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuo Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-58-20210226","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-200203000-00004","article-title":"Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients","volume":"81","author":"Ferri","year":"2002","journal-title":"Medicine (Baltimore"},{"key":"R2-58-20210226","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.rdc.2015.04.006","article-title":"Management of systemic-sclerosis-associated interstitial lung disease","volume":"41","author":"Silver","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"R3-58-20210226","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1183\/16000617.00002915","article-title":"Interstitial lung disease in systemic sclerosis: where do we stand?","volume":"24","author":"Cappelli","year":"2015","journal-title":"Eur Respir Rev"},{"key":"R4-58-20210226","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.autrev.2015.02.002","article-title":"Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?","volume":"14","author":"Iudici","year":"2015","journal-title":"Autoimmun Rev"},{"key":"R5-58-20210226","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"R6-58-20210226","first-page":"235","article-title":"Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease","volume":"31","author":"Miura","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"R7-58-20210226","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4103\/0970-2113.148451","article-title":"Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis","volume":"32","author":"Udwadia","year":"2015","journal-title":"Lung India"},{"key":"R8-58-20210226","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 Classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R9-58-20210226","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","article-title":"Mortality and survival in systemic sclerosis: systematic review and meta-analysis","volume":"44","author":"Rubio-Rivas","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"R10-58-20210226","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-0034-1371543","article-title":"Pulmonary pathology in connective tissue disease","volume":"35","author":"Urisman","year":"2014","journal-title":"Semin Respir Crit Care Med"},{"key":"R11-58-20210226","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.2165\/11207710-000000000-00000","article-title":"Pirfenidone: in idiopathic pulmonary fibrosis","volume":"71","author":"Carter","year":"2011","journal-title":"Drugs"},{"key":"R12-58-20210226","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","article-title":"Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"171","author":"Azuma","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"R13-58-20210226","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1183\/09031936.00005209","article-title":"Pirfenidone in idiopathic pulmonary fibrosis","volume":"35","author":"Taniguchi","year":"2010","journal-title":"Eur Respir J"},{"key":"R14-58-20210226","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"key":"R15-58-20210226","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"R16-58-20210226","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1186\/s13075-014-0510-4","article-title":"Pirfenidone gel in patients with localized scleroderma: a phase II study","volume":"16","author":"Rodr\u00edguez-Castellanos","year":"2015","journal-title":"Arthritis Res Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000004113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:28:10Z","timestamp":1620959290000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201607050-00058"}},"subtitle":["The efficacy of pirfenidone in a Chinese patient with progressive systemic sclerosis-associated interstitial lung disease A CARE-compliant article"],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":16,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000004113","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}